Magstim Acquires Electrical Geodesics, Inc. (EGI) Product Portfolio High-density EEG complements Magstim’s Transcranial Magnetic Stimulation Technology Driving Innovation MINNEAPOLIS, Minn. & Carmarthenshire, UK — (July 2, 2020) – Magstim, the
Magstim Academy Lecture Series – Rhythm and Acceleration – recent advances in TMS treatment for mood disorders. Mark George, MD, Nolan Williams, MD and Martijn Arns, PhD will present on their recently published and on-going TMS studies.
Magstim Academy Lecture Series – this live series will begin on May 12th and cover cutting-edge magnetic stimulation research.
Magstim® TMS has launched the very first Transcranial Magnetic Stimulation navigation system specifically developed for the clinical market.
Magstim has received FDA clearance to include intermittent Theta Burst Stimulation (iTBS) as a treatment for Major Depressive Disorder with its Horizon® TMS Therapy systems.
Take a look inside Magstim. At Magstim, we believe in developing cost-effective, innovative TMS solutions, enabling ground breaking neuroscience research & TMS Therapy. Dr. M. Polson gives us a look
How we treat depression in the future may be set to change as the NHS begins an unprecedented two year study using transcranial magnetic stimulation (TMS).
Magstim Group, Inc., the pioneer in trans-cranial magnetic stimulation and intraoperative nerve monitoring, today announced that it has appointed Lothar Krinke, Ph.D., as Chief Executive Officer effective immediately. Dr. Krinke will serve on the Board of Directors of Magstim. He will be responsible for Magstim and Technomed.
